NL-OMON44603
Completed
Not Applicable
Identifying REsponders and exploring mechanisms of ACTION of the endobronchial coil treatment for emphysema - REACTIO
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- COPD
- Sponsor
- niversitair Medisch Centrum Groningen
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Diagnosis of COPD
- •2\) FEV1%pred \<45% and FEV1/FVC \<60%
- •3\) RV/TLC \>55%
- •4\) TLC%pred \>100% AND RV%pred \>175%
- •5\) Dyspnea scoring \>\=2 on mMRC scale of 0\-4\.
- •6\) Stopped smoking for at least 6 months prior to entering the study.
- •7\) Completed a pulmonary rehabilitation program within 6 months prior to treatment and/or regularly performing maintenance respiratory rehabilitation if initial supervised therapy occurred more than 6 months prior to baseline testing.
- •8\) Received Influenza vaccinations consistent with local recommendations and/or policy.
- •9\) Read, understood and signed the Informed Consent form.
Exclusion Criteria
- •1\) Subject has co\-morbidities that may significantly reduce subject\*s ability to improve exercise capacity (e.g., severe arthritis, planned knee surgery) or baseline limitation on 6MWT is not due to dyspnea.
- •2\) Subject has severe gas exchange abnormalities as defined by: PaCO2 \>8\.0 kPa and/or PaO2 \< 6\.0 kPa (on room air).
- •3\) Subject has a history of recurrent clinically significant respiratory infections, defined as 3 or more hospitalizations for respiratory infection during the year prior to enrolment.
- •4\) Subject has severe pulmonary hypertension defined by right ventricular systolic pressure \>45 mm Hg via echocardiogram.
- •5\) Subject has an inability to walk \>140 meters in 6 minutes.
- •6\) Subject has evidence of other severe disease (such as, but not limited to, lung cancer or renal failure), which in the judgment of the investigator may compromise survival of the subject for the duration of the study.
- •7\) Subject is pregnant or lactating, or plans to become pregnant within the study timeframe.
- •8\) Subject has an inability to tolerate bronchoscopy under conscious sedation or general anaesthesia.
- •9\) Subject has clinically significant bronchiectasis.
- •10\) Subject has giant bullae \>1/3 lung volume.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Identifying which patients will benefit from the UPLIFT programPersistent low back painMusculoskeletal - Other muscular and skeletal disordersACTRN12618001525279Kerrie Evans246
Recruiting
Not Applicable
Identification ofresponders/non-responders to gut-microbiome mediated conversion of dietary phytochemicalsNot ApplicableKCT0008602Ewha Womens University200
Not yet recruiting
Not Applicable
Biomarkar data analysis to find out patients of lung and head and neck cancer who responded to treatment and who did not respond to treatmentHealth Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynxHealth Condition 2: C349- Malignant neoplasm of unspecifiedpart of bronchus or lungCTRI/2024/03/063428Tata Memorial Centre
Completed
Not Applicable
Revealing mechanisms and investigating efficacy of hemoadsorption for prevention of vasodilatory shock in cardiac surgery patients with infective endocarditis – a multicentric randomized controlled group sequential trialI33.0Acute and subacute infective endocarditisDRKS00013740Center for Sepsis Control & Care Universitätsklinikum Jena288
Completed
Not Applicable
The contributing factors to the responsiveness of inhaled corticosteroids in patients with untreated asthmaasthmaJPRN-UMIN000021486agoya City University Dept of Respiratory Medicine, Allergy and Clinical Immunology13